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Diagnosis of CF based on diagnostic algorithms is unsatisfactory due to inadequacy of
genotyping and considerable overlap and poor concordance with sweat chloride (SC)
and nasal potential difference (NPD). We evaluated a novel approach using principal
components analysis (PCA) as a diagnostic determinant of CF. PCA is not dependent
on assumptions of original test cutoffs and can integrate multiple variables (SC&NPD)
while retaining information of the original variables.
Methods: Patients with suspected CF (Q), and reference non-CF (healthy individuals
[CON] and obligate heterozygotes [HET]) and CF subjects (PS&PI) were evaluated
by genotyping, SC&NPD. PCA was performed on various combinations of SC and
NPD parameters. Based on PCA, the risk of CF diagnosis ranging from 0 to 100%,
was determined by logistic regression.
Results: Optimal separation, with no overlap, was observed between CF and non-CF
individuals with PCA of SC and 2 NPD parameters (DCl-free+Iso and DAmil+Cl-
free+Iso) (Table). There was contiguity of dysfunction and probability of CF diagnosis
from CON to HET at one extreme to CFPS and CFPI at the other. Similar contiguity
was observed in Q patients, which correlated with the number (0, 1 or 2) and severity
of CFTR mutations (CF- or not CF-causing).
Conclusion: An integrated ion channel measurement may offer optimal determination
of the risk of a CF diagnosis, in patients with an uncertain diagnosis of CF.
Integrated ICM and probability of CF diagnosis
Group N PCA of integrated ion channel measurement: SC, DCl-free+Iso and
DAmil+Cl-free+Iso; value (probability of CF, %)
Min Lower
quartile
Median Upper
quartile
Max
CON 84 −4.4 (0) −2.1 (0) −1.4 (0.1) −1 (0.7) −0.2 (29.3)
HET 48 −3 (0) −1.7 (0) −0.9 (1.0) −0.6 (5.0) −0.2 (27.3)
CFPS 64 0.2 (64.4) 0.9 (98.4) 1.5 (99.9) 2.1 (100) 3.4 (100)
CFPI 43 1.4 (99.9) 2.3 (100) 2.6 (100) 2.8 (100) 3.7 (100)
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A diagnostic algorithm, incorporating CFTR genotyping, sweat chloride (SC) and other ion channel
tests e.g. nasal potential difference (NPD), has been developed by ECFS to assist CF diagnosis
(Thorax 2006;61;627–635). We used prospectively ascertained data to independently test the validity
of the algorithm.
Methods: Patients with suspected CF (Q: idiopathic sinopulmonary disease, idiopathic pancreatitis,
obstructive azoospermia) and reference groups of healthy individuals (CON), obligate heterozygotes
(HET) and CF patients (PS and PI) were evaluated. No prior assumptions were made for the diagnostic
reference range for NPD since none has been established or validated. Hence, reference ranges were
based on the degree of overlap between CF and non-CF individuals.
Results: Variable overlap occurred in SC&NPD between CF and non-CF (Table). Observed
agreement between SC&NPD was 95% in CFPI and CON groups but suboptimal in CFPS and
Q groups (conﬁrmed on Kappa [ú] statistic; excellent agreement if ú > 0.8). Genotyping offered no
additional diagnostic yield.
Conclusion: Diagnosis of CF, by genotyping and using SC&NPD separately and stepwise, is
unsatisfactory; not only in uncertain cases but also in a small number of patients with clear-cut
normal/abnormal results.
Outcomes and concordance of diagnostic evaluation.
Group N 2CF causing SC (mmol/L): NPD Observed agreement, ú (95%CI):
mutations:
n (%)
median, range DCl−
free+iso
(mV):
median,
range
eDCl−free+Iso/Damil :
median, range
SC and
DCl−free+iso
SC and
eDCl−free+Iso/Damil
CON 84 0 18, 10−52 −23,
−59 to −8
0.11, 0.00−0.61 95%; −0.02
(−0.05, 0.00)
100%; −
HET 48 0 24, 10−59 −19,
−48 to −8
0.29, 0.02−0.57 69%; −0.15
(−0.26, −0.04)
100%; −
Idiopathic
sinopulmonary
disease
72 4 (6%) 25, 10−89 −13,
−51 to 14
0.35, 0.00−6.05 77%; 0.58
(0.40, 0.76)
87%; 0.64 (0.43, 0.85)
Idiopathic
pancreatitis
44 2 (5%) 24, 10−100 −15,
−60 to 8
0.29, 0.00−1.85 64%; 0.10
(−0.13, 0.33)
76%; −0.08
(−0.17, 0.01)
Obstructive
azoospermia
92 4 (4%) 44, 10−108 −9,
−40 to −5
0.61, 0.03−1.28 44.6%; 0.24
(0.09, 0.40)
62%; 0.22 (0.05, 0.39)
CFPS 64 28 (44%) 67, 10−125 0,
−12 to 14
1.00, 0.61−1.95 64%; 0.04
(−0.07, 0.15)
64%; 0.00 (0.00)
CFPI 43 38 (88%) 102, 68−121 3,
−4 to 17
1.10, 0.85−3.21 100%; − 100%; −
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Background: The term CFTR-related disease describes individuals with CF phe-
notype or positive neonatal screening (NBS), normal or borderline sweat chloride
test (SCT) and one disease-causing mutation on each CFTR gene.
Aim: To characterize the clinical features and the long-term follow-up of patients
with CFTR-related disease followed at our Center.
Patients and Methods: We studied 68 subjects (41 females) responding to the
deﬁnition of CFTR-related disease. Median age was 7.9 yrs (range 0.2−25 yrs),
median follow-up time 5.6 yrs. CFTR mutation screening was performed with
DGGE, DHPLC and sequencing. Pancreatic status was established by means of
faecal elastase.
Results: Diagnosis occurred by means of NBS in 50 (73.5%) and by symptoms
in 18 (26.5%). All 68 subjects are compound eterozygous carrying at least one
mild mutation and all are pancreatic sufﬁcient. At the ﬁrst visit, 34 (68%) of
infants diagnosed by NBS were asymptomatic. Children diagnosed by symptoms
had mostly respiratory symptoms (12 pts, 68.8%) with lower RTI in 10. During the
follow-up 22 children became symptomatic mainly with URTI; their SCT values
were higher (44 vs 30 mEq/l Cl) than those found in patients who remained
asymptomatic. Pts >10 yrs of age show more evident lung disease (50% Gram
neg colonization).
Conclusions: Pts with CFTR-related disease are pancreatic sufﬁcient and most have
a borderline or negative SCT. They show no symptoms in early life and mild lung
disease beyond the age of 10 yrs. NBS programs result in increasing detection of
CFTR related-disease.
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Introduction: Three neonates with jejunal or ileal atresia (JIA) were diagnosed with
CF in a year time, only after a considerable doctor’s delay. In one of those cases
the diagnosis was established post-mortem. A neonate presenting with meconium
ileus will lead neonatologists and surgeons to perform CF analysis, but JIA may
not.
Aims and Objectives: Analysis of all cases of JIA in a University Hospital with a
Neonatal Intensive Care Unit (NICU) and a dedicated CF-team.
Methods: Retrospective chart review and comparison with current literature.
Results: In our hospital, in an 18 year period (1991–2008), 55 children presented
with JIA. CF was only considered in 19/55 cases (35%), which led to 4 diagnosed
cases (4/19, 21% of those considered) with a sweat test (n = 3) or CFTR analysis
(n = 1). Of the four children with CF, one was diagnosed in the ﬁrst month after
birth, another at age four months, and the other two at age seven months (one was
post-mortem).
In current international pediatric (including CF), surgical and genetic textbooks,
as well as in the OMIM database, JIA is not mentioned as a possible presenting
clinical feature of CF and therefore not listed as an indication to perform a sweat
test or DNA analysis. In the few PubMed-cited articles reporting this association,
the prevalence of CF in JIA patients is approximately 10% (range 8−11%).
Conclusion: In our hospital the, scarcely reported, association between JIA and CF
was underappreciated until now. Physicians treating neonates with bowel obstruction
must be aware of the reported prevalence of approximately 10% CF in JIA and act
accordingly.
Jejunal or ileal atresia: consider CF!
